Sale allows Forbes to focus on functional foods

by Jeff Gelski
Share This:

VANCOUVER, B.C. — Forbes Medi-Tech Inc. has sold its pharmaceutical and business unit in San Diego to Transition Therapeutics Inc., Toronto. Forbes will receive an upfront payment of $1 million and potential future payments of $6 million.

"As highlighted in a recent news release, this initiative will reduce the company’s burn rate while allowing Forbes to clearly focus on further developing its nutraceutical business — through both organic growth and M.&A. initiatives within the functional food and dietary supplement markets," said Charles Butt, president and chief executive officer of Forbes Medi-Tech, when the deal was announced Aug. 18.

Forbes in May said it planned to focus exclusively on its revenue-generating nutraceutical business for functional foods and dietary supplements. The company offers a phytosterol product portfolio, including the Reducol brand.

Comment on this Article
We welcome your thoughtful comments. Please comply with our Community rules.



The views expressed in the comments section of Food Business News do not reflect those of Food Business News or its parent company, Sosland Publishing Co., Kansas City, Mo. Concern regarding a specific comment may be registered with the Editor by clicking the Report Abuse link.